Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.4.2.30 (
PARP
)
13,611
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
ADP-ribosylation is a covalent posttranslational modification of proteins that is catalyzed by various types of
ADP-ribosyltransferase
(
ART
) enzymes, including members of the poly(ADP-ribose) polymerase (
PARP
) family. ADP-ribose (ADPR) modifications can occur as mono(ADP-ribosyl)ation, oligo(ADP-ribosyl)ation, or poly(ADP-ribosyl)ation, depending on the particular
ART
enzyme catalyzing the reaction, as well as the specific reaction conditions. Understanding the biology of ADP-ribosylation requires facile and robust means of generating and detecting the modification in all of its forms. Here we describe how to generate protein-linked mono(ADP-ribose), oligo(ADP-ribose), and poly(ADP-ribose) (MAR,
OAR
, and PAR, respectively) in vitro as an automodification of PARPs 1 or 3. First, epitope-tagged
PARP-1
(a
PARP
polyenzyme) and PARP-3 (a
PARP
monoenzyme) are expressed individually in insect cells using baculovirus expression vectors, and purified using immunoaffinity chromatography. Second, the purified recombinant PARPs are incubated individually in the presence of different concentrations of NAD
+
(as a donor of ADPR groups) and sheared DNA (to activate their catalytic activities) resulting in various forms of auto-ADP-ribosylation. Third, the products are confirmed using ADPR detection reagents that can distinguish among MAR,
OAR
, and PAR. Finally, if desired, the
OAR
and PAR can be deproteinized. The protein-linked and free MAR,
OAR
, and PAR generated in these reactions can be used as standards, substrates, or binding partners in a variety of ADPR-related assays.
...
PMID:Generating Protein-Linked and Protein-Free Mono-, Oligo-, and Poly(ADP-Ribose) In Vitro. 3120 27